# Early Clinical Study of JY306 Universal NK Cell Injection in the Treatment of Adult Relapsed or Refractory CD70+ Malignant Hematologic Tumors

> **NCT06837389** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 18 (estimated)

## Conditions studied

- Relapsed or Refractory Hematological Malignancies

## Interventions

- **BIOLOGICAL:** JY306 universal NK cell injection

## Key facts

- **NCT ID:** NCT06837389
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-15
- **Primary completion:** 2026-03-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06837389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06837389, "Early Clinical Study of JY306 Universal NK Cell Injection in the Treatment of Adult Relapsed or Refractory CD70+ Malignant Hematologic Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06837389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*